Patients with baseline tachycardia, autonomic dysfunction, or cardiac conditions warrant closer monitoring and provider guidance before initiating therapy
Figure 2 : Percentage change in body weight with tirzepatide 5mg, 10mg, and 15mg versus placebo 9 Although, no trial compares tirzepatide to semaglutide at the target dose approved for weight loss, inferences can be drawn by comparing the results of the SURMOUNT I trial and the STEP I trial
From SURMOUNT-1 reanalysis at week 4: 2.5 mg arm: average weight change -1.2% (about 2.5 lb for a 200 lb starting weight) 5 mg arm: average weight change -2.1% (about 4.2 lb) 10 mg arm: average weight change -2.6% (about 5.2 lb) 15 mg arm: average weight change -2.9% (about 5.8 lb) Placebo arm: average weight change -0.4% The headline 21% weight loss number from SURMOUNT-1 is the 72-week result at 15 mg
Position sizing matters across the three, because the risk profiles are not interchangeable
It is also available as a combination product (phentermine + topiramate) under the brand name Qsymia for use in adults and children 12 years of age and older